M.D. Anderson Cancer Center
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Primary Objective: The primary objective of the study is to determine the efficacy of CB-derived CD70.CAR NK cell therapy in patients with primary refractory or early relapsed DLBCL and HL, as determined by the 2-year event-free survival rate. Secondary Objectives: * To determine the antitumor activity pf CB-derived CD70.CAR NK cells, as determined by the response rate (ORR) and complete response (CR) rate. * To establish the safety of this treatment. * To quantify the persistence of infused CB-derived CD70.CAR NK cells in the peripheral blood. * To conduct comprehensive immune studies by e…
Inclusion Criteria: 1. 18-75 years of age. 2. Diagnosis of cHL or DLBCL that is either: * Primary refractory, defined as not having achieved a CR with frontline therapy or having relapsed within 3 months. * Early relapsed (≤ 12 months) after achieving a CR to frontline therapy. 3. Tumor biopsy positive for CD70 \>/= 10% by immunohistochemistry or flow cytometry. 4. Measurable disease, defined by one or more histologically confirmed hypermetabolic lesion on PET/CT scan. 5. ECOG PS ≤ 2 (Karnofsky ≥60%). 6. Adequate blood counts (WBC \> 2K, HGB \> 8 g/dL, platelets \> 50K). 7. Creatinine…
Given by IV
Given by IV
Given by IV Infusion
Given by IV Infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.